Survey Results On SSRIs

An original-research post using the large SSC survey (2,090 SSRI users) as a tool to probe open SSRI questions. Findings: ~63% felt better (with the placebo caveat noted); an efficacy ranking (Lexapro 5.7 / Zoloft / Prozac / Celexa > Paxil 4.6, with Paxil's gap likely side-effect-driven) that correlates r=0.98 with his earlier drugs.com analysis; SSRIs work notably better for anxiety (5.9) than depression (5.3) -- 'as far as I know this is the first study to back this claim up'; 70% report at least one side effect (sexual 52%, emotional blunting 39%); and the striking, underdiscussed result that 15% of people who stopped >5 years ago say their side effects (mostly sexual) never went away -- a much higher post-SSRI-sexual-dysfunction rate than the literature implies. Discontinuation: Paxil hardest, Prozac easiest (confirming consensus); a slower taper correlated with WORSE problems (reverse causation -- doctors taper slowly when they expect trouble), and cold-turkey-by-running-out was worst. Honest about confounds (dose, recall bias) and the survey's limits. A genuinely useful clinical survey with a couple of real contributions, not a bare data dump.

Quality 65 · Strong. Low-Strong (65): a substantive, well-analyzed survey that exploits SSC's large N to deliver real clinical findings (the anxiety>depression effect, the r=0.98 external replication, the surprisingly high persistent-side-effects number) and informs Scott's own prescribing. Low-Strong rather than higher because it is survey-driven and mostly conveys or confirms existing clinical knowledge, with the usual self-acknowledged methodological caveats.

Claude’s paradigm shift 42 · Moderate. Moderate (42): using the survey as a large-N research instrument and surfacing the (claimed-first) anxiety>depression result are modest novel contributions, but most results confirm known consensus.

Real-world impact 2 · Minor. Original SSC-survey research delivering real clinical findings (the anxiety>depression effect, side-effect rates) that informs his own prescribing; substantive within the discourse but with no broad practice or material-world reach → RWI 2.